Glycoprotein News and Research

RSS

UAB researchers find potential new pathway to treating radiation-resistant glioblastoma

Researchers at the University of Alabama at Birmingham have identified a potential new pathway to treating radiation-resistant glioblastoma, one of the most aggressive forms of brain cancer.

15 Mar 2021

Dual-action monoclonal antibodies from an original SARS survivor show promise against COVID-19

A recent study, currently available on the bioRxiv preprint server, indicates that a pair of dual-action monoclonal antibodies derived from an original 2003 SARS survivors could play an important role in the fight against coronavirus disease 2019 (COVID-19) due to their broadly neutralizing activity and the engagement of the immune system via effector function capabilities.

14 Mar 2021

Study identifies three novel binding receptors for SARS-CoV-2

A team of scientists from the United Kingdom recently conducted a large-scale screening of several membrane-bound and soluble host cell receptors to identify novel binding partners for SARS-CoV-2. They have identified three novel receptors expressed on the human cell membrane; of which, one binds to SARS-CoV-2 spike with similar affinity as angiotensin-converting enzyme 2 (ACE2).

12 Mar 2021

Natural virus-induced immunity protective against UK and South African SARS-CoV-2 variants in hamster study

As new variants of SARS-CoV-2 continue to emerge, fueling the continued spread of the COVID-19 pandemic, a new study offers encouragement.

12 Mar 2021

N501Y mutation in SARS-CoV-2 responsible for increased viral transmission

Researchers at the University of Texas, USA, have confirmed the specific mutation in the B.1.1.7 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), has allowed for it to be more transmissible than the ancestral strain. The N501Y substitution is one of 8 spike protein substitutions present in the UK variant and has also appeared convergently in the Brazil (P.1) and South Africa (B.1.351) variants.

11 Mar 2021

SARS-CoV-2 spike S1 subunit induces hypercoagulability

The vascular complications of the condition include a range of various coagulopathies that cause bleeding and thrombocytopenia or a hypercoagulable state. A new preprint research paper posted to the medRxiv server describes the role of a fibrinogen-related protein in inducing these clinical features of COVID-19.

10 Mar 2021

Researchers discover new COVID-19 variants in three South African provinces

Variants of the coronavirus are appearing in different parts of the world, many of them spreading with alarming speed.

10 Mar 2021

Research demonstrates multivalent nanobodies overcome SARS-CoV-2 variant mutations

In a recent bioRxiv* preprint paper, researchers isolated anti-RBD nanobodies from llamas and “nanomice” (they engineered to produce VHHs cloned from alpacas, dromedaries and camels).

10 Mar 2021

Optimized SARS-CoV-2 vaccine candidate could be less reactogenic, say researchers

A new study, released as a preprint on the bioRxiv* server, reports an optimized coronavirus disease 2019 (COVID-19) vaccine candidate, which, claim the researchers, may be less likely to produce reactions like fevers. It may also have increased protective potential against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen that causes COVID-19.

9 Mar 2021

Delayed detection of oral fluid anti-SARS-CoV-2 antibodies increases the time to viral clearance

A prospective observational study has revealed that the late appearance of anti-SARS-CoV-2 antibodies in oral fluid, absence of fever as an early symptom, and elevated BMI are associated with delayed clearance of viral RNA in mild to moderate COVID-19 patients.

4 Mar 2021

Cell surface marker CD47 may allow early diagnosis of severe COVID-19

A new study reports the potential of the cell surface marker, CD47, as a biomarker for hyperinflammation, a characteristic feature of severe COVID-19.

4 Mar 2021

Study shows lower antibody cross-reactivity after infection with the B.1.1.7 SARS-CoV-2 variant

In a recent research paper currently available on the bioRxiv* preprint server, a diverse group of researchers has examined the immunogenicity of antibodies against the variant B.1.1.7 of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) initially found in the United Kingdom – and revealed diminished recognition and neutralization of either parental strains or the South African variant.

3 Mar 2021

Enduring antibody response observed after natural immunity and first Pfizer SARS-CoV-2 vaccine shot

Immunity gained after natural infection from the acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is boosted when people take the first Pfizer-BioNTech vaccine, according to a new study led by Iain C. Chapple from the University of Birmingham.

1 Mar 2021

A backbone free energy study of SARS-CoV-2 variants of concern

A recent study by scientist Robert Penner at the Institut des Hautes Études Scientifiques in France utilizes free energy calculations to predict effective antiviral targets that are highly conserved, surface-accessible for interaction, and resistant to mutation.

1 Mar 2021

Inhalable nanobody shows potent anti-SARS-CoV-2 activity in vivo

Researchers have developed a stable and ultrapotent homotrimeric Pittsburgh inhalable Nanobody 21 (PiN-21) against SARS-CoV-2 infection in Syrian hamsters. They demonstrated the high therapeutic efficacy of this homotrimeric Nb, leveraging both intranasal and aerosol delivery.

26 Feb 2021

Basigin does not facilitate SARS-CoV-2 entry, say researchers

Researchers investigated the significance of a transmembrane glycoprotein basigin, or CD147, as a host cell co-receptor required for the entry of SARS-CoV-2. The findings reveal that recombinant human basigin does not interact with full-length spike protein or spike RBD of SARS-CoV-2.

24 Feb 2021

L452R mutation potentially favors adaptive evolution of SARS-CoV-2

A team of scientists from the United States recently investigated the mutational signatures in the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein.

23 Feb 2021

An overview of spike protein antigen COVID-19 vaccine candidates

A new paper in the journal Reviews in Medical Virology provides a perspective on current vaccine development strategies and tools, which may allow the production of safe and effective vaccines.

22 Feb 2021

Superspreader events trigger emergence of novel SARS-CoV-2 variants in USA

A team of scientists from the USA and Germany has recently studied the evolution of SARS-CoV-2 in a representative set of sequences from the USA collected between 2020 and 2021. The findings reveal that the viral genome has accumulated multiple mutations over time with only occasional loss of mutation. The main driving forces behind such genetic variations include widespread infection and superspreader events.

22 Feb 2021

Polyphenols may provide protective effect against COVID-19 disease

In the study published in the journal Integrative Physiology, the researchers found that a high intake of polyphenols may have a protective effect on patients with COVID-19 and prevent disease progression.

22 Feb 2021

Glycoprotein News and Research

UAB researchers find potential new pathway to treating radiation-resistant glioblastoma

Dual-action monoclonal antibodies from an original SARS survivor show promise against COVID-19

Study identifies three novel binding receptors for SARS-CoV-2

Natural virus-induced immunity protective against UK and South African SARS-CoV-2 variants in hamster study

N501Y mutation in SARS-CoV-2 responsible for increased viral transmission

SARS-CoV-2 spike S1 subunit induces hypercoagulability

Researchers discover new COVID-19 variants in three South African provinces

Research demonstrates multivalent nanobodies overcome SARS-CoV-2 variant mutations

Optimized SARS-CoV-2 vaccine candidate could be less reactogenic, say researchers

Delayed detection of oral fluid anti-SARS-CoV-2 antibodies increases the time to viral clearance

Cell surface marker CD47 may allow early diagnosis of severe COVID-19

Study shows lower antibody cross-reactivity after infection with the B.1.1.7 SARS-CoV-2 variant

Enduring antibody response observed after natural immunity and first Pfizer SARS-CoV-2 vaccine shot

A backbone free energy study of SARS-CoV-2 variants of concern

Inhalable nanobody shows potent anti-SARS-CoV-2 activity in vivo

Basigin does not facilitate SARS-CoV-2 entry, say researchers

L452R mutation potentially favors adaptive evolution of SARS-CoV-2

An overview of spike protein antigen COVID-19 vaccine candidates

Superspreader events trigger emergence of novel SARS-CoV-2 variants in USA

Polyphenols may provide protective effect against COVID-19 disease

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News